 Anixa Biosciences, Inc. NASDAQ: ANIX, a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 and announced discovery of its first potential Covid-19 candidate two weeks later on May 4, 2020. 